0
1
Letter to the Editor   |    
Violent Behavior Associated With Donepezil
W. P. BOUMAN, M.D.; G. PINNER, M.D.
Am J Psychiatry 1998;155:1626a-1626.
View Article Information
Letters to the Editor
To the editor: We report a case of violent behavior following the commencement of donepezil, the first recently introduced reversible cholinesterase inhibitor in this country. The indication for donepezil is symptomatic treatment of mild or moderate dementia in Alzheimer"s disease. Donepezil is thought to work by increasing the availability of intrasynaptic acetylcholine in the brains of patients with Alzheimer"s disease (1).
Mr. A, a 76-year-old man with a 2-year history of cognitive impairment, was clinically diagnosed as suffering from Alzheimer"s disease according to ICD-10 (2). His Mini-Mental State score (3) was 17 of 30. There was no history of violence or behavioral disturbances, and no psychotic phenomena were elicited. Apart from an unstable bladder requiring prescription of oxybutinin, 3 mg t.i.d. for the past 5 years, Mr. A’s medical history was unremarkable. A physical examination and routine laboratory investigations showed no abnormalities, apart from an intermittent parkinsonian tremor of his left hand. This raised the possibility of a diagnosis of dementia with Lewy bodies (4), although no other features were present. Mr. A was started on a regimen of donepezil, 5.0 mg daily.
Five days later, Mr. A became very paranoid, believing that his wife had been stealing his money. He beat his wife and held her hostage in their house with a knife until their daughter intervened. Mr. A agreed to hospital admission, avoiding compulsory detention.
Physical and laboratory investigations were repeated, including a computerized tomography scan of the brain showing no abnormalities apart from generalized atrophy. Mr. A was started on a regimen of haloperidol, 0.5 mg b.i.d., while his donepezil and oxybutinin were discontinued. His paranoid ideation resolved within a few days and did not reoccur, despite withdrawal of haloperidol.
Although a causal relationship between this violent incident and donepezil cannot be proven, a temporal relationship between the commencement of donepezil and the occurrence of behavioral disturbance in Mr. A, a patient with no previous history of violence, warrants caution with the prescription of this drug. The manufacturer reports that 5% of patients taking donepezil have developed agitation, although only 1% with physical aggression (personal communication). We suggest the need for close specialist monitoring of this recently licensed drug.
Rogers SL, Friedhoff LT: The efficacy and safety of donezepil in patients with Alzheimer"s disease: results of a US multicentre, randomized, double blind, placebo-controlled trial. Dementia  1996; 7:293–303[PubMed]
 
World Health Organization: The ICD-10 Classification of Mental and Behavioural Disorders. Geneva, WHO, 1992
 
Folstein MF, Folstein SE, McHugh PR: Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res  1975; 12:189–198[PubMed][CrossRef]
 
McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology  1996; 47:1113–1124[PubMed]
 
+
Rogers SL, Friedhoff LT: The efficacy and safety of donezepil in patients with Alzheimer"s disease: results of a US multicentre, randomized, double blind, placebo-controlled trial. Dementia  1996; 7:293–303[PubMed]
 
World Health Organization: The ICD-10 Classification of Mental and Behavioural Disorders. Geneva, WHO, 1992
 
Folstein MF, Folstein SE, McHugh PR: Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res  1975; 12:189–198[PubMed][CrossRef]
 
McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology  1996; 47:1113–1124[PubMed]
 
+
+

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of JBJS editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content
Articles
Books
What Your Patients Need to Know About Psychiatric Medications, 2nd Edition > Chapter 73.  >
Topic Collections
Psychiatric News
PubMed Articles